

# UC Davis

## UC Davis Previously Published Works

### Title

Decision quality and regret with treatment decisions in women with breast cancer: Pre-operative breast MRI and breast density

### Permalink

<https://escholarship.org/uc/item/8kn9g3cn>

### Journal

Breast Cancer Research and Treatment, 194(3)

### ISSN

0167-6806

### Authors

Wernli, Karen J  
Smith, Rebecca E  
Henderson, Louise M  
[et al.](#)

### Publication Date

2022-08-01

### DOI

10.1007/s10549-022-06648-7

Peer reviewed



Published in final edited form as:

*Breast Cancer Res Treat.* 2022 August ; 194(3): 607–616. doi:10.1007/s10549-022-06648-7.

## Decision quality and regret with treatment decisions in women with breast cancer: Pre-operative breast MRI and breast density

Karen J. Wernli, PhD<sup>1</sup>, Rebecca E. Smith, MS<sup>2</sup>, Louise M. Henderson, PhD<sup>3</sup>, Wenyan Zhao, PhD<sup>2</sup>, Danielle D. Durham, PhD<sup>3</sup>, Karen Schifferdecker, PhD<sup>2</sup>, Celia Kaplan, PhD<sup>4</sup>, Diana S. M. Buist, PhD<sup>1</sup>, Karla Kerlikowske, MD<sup>4</sup>, Diana L. Miglioretti, PhD<sup>5,1</sup>, Tracy Onega, PhD<sup>6</sup>, Nila H. Alsheik, MD<sup>7</sup>, Brian L. Sprague, PhD<sup>8</sup>, Gloria Jackson-Nefertiti<sup>5</sup>, Jill Budesky<sup>5</sup>, Dianne Johnson<sup>5</sup>, Anna N. A. Tosteson, ScD<sup>2</sup>

<sup>1</sup>Kaiser Permanente Washington Health Research Institute, Seattle WA

<sup>2</sup>Geisel School of Medicine at Dartmouth and Norris Cotton Cancer Center, Lebanon NH

<sup>3</sup>University of North Carolina-Chapel Hill, Chapel Hill NC

<sup>4</sup>University of California-San Francisco, San Francisco CA

<sup>5</sup>University of California-Davis, Davis CA

<sup>6</sup>University of Utah, Salt Lake City UT

<sup>7</sup>Advocate Aurora Health Care, Park Ridge, IL

<sup>8</sup>University of Vermont, Burlington VT

### Abstract

**Purpose:** We evaluated self-report of decision quality and regret with breast cancer surgical treatment by pre-operative breast MRI use in women recently diagnosed with breast cancer.

**Methods:** We conducted a survey with 957 women aged 18+ with stage 0-III breast cancer identified in the Breast Cancer Surveillance Consortium. Participants self-reported receipt of pre-operative breast MRI. Primary outcomes were process measures in the Breast Cancer Surgery Decision Quality Instrument (BCS-DQI) (continuous outcome) and Decision Regret Scale (dichotomized outcomes as any/none). Generalized estimating equations with linear and logit

---

**Corresponding author:** Karen J. Wernli PhD, Kaiser Permanente Washington Health Research Institute, 1730 Minor Ave, Suite 1600, Seattle, WA 98101, Phone: 206-287-2934, Karen.J.Wernli@kp.org.

#### AUTHOR CONTRIBUTIONS

**Conceived and designed the analysis:** Karen J. Wernli, Rebecca E. Smith, Louise M. Henderson, Wenyan Zhao, Danielle D. Durham, Karen Schifferdecker, Celia Kaplan, Anna N. A. Tosteson

**Collected the data:** Rebecca E. Smith, Louise M. Henderson, Diana S. M. Buist, Karla Kerlikowske, Diana L. Miglioretti, Tracy Onega, Nila H. Alsheik, Brian L. Sprague, Anna N. A. Tosteson

**Contributed data or analysis tools:** Karen J. Wernli, Rebecca E. Smith, Louise M. Henderson, Diana S. M. Buist, Karla Kerlikowske, Diana L. Miglioretti, Tracy Onega, Nila H. Alsheik, Brian L. Sprague, Anna N. A. Tosteson

**Performed the analysis:** Rebecca E. Smith, Wenyan Zhao

**Wrote the paper:** Karen J. Wernli, Rebecca E. Smith, Louise M. Henderson, Wenyan Zhao, Danielle D. Durham, Karen Schifferdecker, Celia Kaplan, Diana S. M. Buist, Karla Kerlikowske, Diana L. Miglioretti, Tracy Onega, Nila H. Alsheik, Brian L. Sprague, Gloria Nefertiti-Jackson, Jill Budesky, Dianne Johnson, Anna N. A. Tosteson

#### AUTHOR DISCLOSURE OF CONFLICTS OF INTEREST

Karla Kerlikowske reports being a nonpaid consultant for GRAIL for STRIVE Study. Diana Miglioretti reports receiving an Honorarium from the Society for Breast Imaging for giving a keynote lecture. All other study authors report no conflicts of interest.

link were used to estimate adjusted associations between breast MRI and primary outcomes. All analyses were also stratified by breast density.

**Results:** Survey participation rate was 27.9% (957/3430). Study population was primarily >60 years, White, college educated, and diagnosed with early-stage breast cancer. Pre-operative breast MRI was reported in 46% of women. A higher proportion of women who were younger age (<50 years), commercially insured, and self-detected their breast cancer reported pre-operative breast MRI use. In adjusted analysis, pre-operative breast MRI use compared with no use was associated with a small but statistically significantly higher decision quality scores (69.5 vs 64.7, p-value=0.043). Decision regret did not significantly differ in women who reported versus not reporting a pre-operative breast MRI (54.2% v. 48.7%, respectively, p-value=0.11). Study results did not vary when stratified by breast density for either primary outcome.

**Conclusions and relevance:** Breast MRI use in the diagnostic work-up of breast cancer does not negatively alter women's perceptions of surgical treatment decisions in early survivorship.

**Clinical Trials Registration Number:** [NCT03029286](https://clinicaltrials.gov/ct2/show/study/NCT03029286).

### Keywords

Breast MRI; breast cancer; mastectomy; decision quality; patient-reported outcomes; BCSC

## INTRODUCTION

Pre-operative breast MRI use in women newly diagnosed with breast cancer has increased in the past 20 years as part of the diagnostic work-up for surgical evaluation for cancer treatment.<sup>1,2</sup> Based on the Breast Cancer Surveillance Consortium (BCSC) data linked to Medicare claims, pre-operative breast MRI increased more than 3-fold from 7.0% in 2005 to 24.3% in 2009 among women with invasive breast cancer.<sup>2</sup> National Comprehensive Cancer Network (NCCN) breast cancer guidelines state that pre-operative breast MRI could be used for staging evaluation or neoadjuvant systemic therapy evaluation.<sup>3</sup> However, NCCN guidelines also state breast MRI should not be used to guide local therapy decisions as no high-quality data demonstrate improvements in local recurrence or survival.<sup>4,5</sup> A decision-analytic model demonstrated that preoperative breast MRI conferred no additional advantage to routine imaging evaluation for women with early stage breast cancer.<sup>6</sup> Study authors concluded that preoperative breast MRI could lead to worse patient outcomes as more women might unnecessarily undergo mastectomy, if they were uncertain about surgical choice.

To date, limited evidence exists regarding imaging and treatment decisions on patient-centered outcomes, including outcomes such as decision quality with respect to initial surgery, more extensive surgery due to re-excision/reoperation, and cancer worry and fear.<sup>7-9</sup> The diagnostic work-up period is a particularly vulnerable time for women newly diagnosed with breast cancer. In a recent systematic review, the diagnostic work-up period is described as one of heightened psychological distress for women, with short- and long-term implications for mental health, treatment decision-making, and future screening participation.<sup>10,11</sup> Pre-operative breast MRI use could lead some women to negatively experience their surgical treatment decision, because use of breast MRI is associated with

delays in cancer surgery and higher overall costs.<sup>12</sup> However, some women, in particular women with dense breasts, might feel reassured with pre-operative breast MRI use to guide their surgical treatment decision if they fear missed cancer. Women with dense breasts are more likely to experience masking of breast cancer,<sup>13</sup> and have an increased risk of contralateral breast cancer compared to women with non-dense breasts,<sup>14</sup> which would support these concerns. To date, few studies have evaluated women's perspectives regarding the use of breast MRI and the association with decision quality as women transition into early survivorship.

Our objective was to evaluate decision quality and regret with breast cancer surgical treatment decisions by pre-operative breast MRI use. We stratified all analyses by breast density to determine if observed results differed by women with and without dense breasts.

## METHODS

### Setting

The BCSC is a network of breast imaging registries that link data from community-based radiology facilities to state or Surveillance, Epidemiology, and End Results (SEER) cancer registries and pathology databases.<sup>15</sup> This study used data from seven registries: Carolina Mammography Registry, Kaiser Permanente Washington, New Hampshire Mammography Network, San Francisco Mammography Registry, Sacramento Area Breast Imaging Registry, Metro Chicago Breast Cancer Registry, and Vermont Breast Cancer Surveillance System.<sup>16</sup> The BCSC collects demographic and clinical data at imaging exams conducted during routine clinical care. Registries send standardized data to a Statistical Coordinating Center for pooling, linking of relevant data files, and statistical analysis.

Each registry and the Statistical Coordinating Center received institutional review board approval for passive permission, or a waiver of written informed consent to identify and conduct an online survey. All procedures were Health Insurance Portability and Accountability Act compliant. The study authors had control of the data and information submitted for publication.

### Participants

Eligible participants were aged 18 years or older at diagnosis of incident breast cancer (stage 0-III) and diagnosed within 6-18 months at identification for recruitment from a BCSC registry. All participants had a digital mammogram or breast tomosynthesis scan within five years of their breast cancer diagnosis documented within a BCSC registry.

### Recruitment

BCSC registries contacted 3,430 potentially eligible participants by US postal service to invite them to participate in a survey. Survey recruitment and completion ran from December 2017 through January 2020. All participants were invited to complete the online survey via a secure web portal using a unique identification number and password. Additionally, six of the seven registries offered a paper-based survey in their invitation letters and provided pre-paid envelope to return survey. One registry also offered participants

survey completion via telephone. Potential participants were reminded three times to complete their survey. Six registries included \$2 bills in their recruitment letters as an incentive, to improve participant response.<sup>17</sup> As a further incentive, participants from five registries were entered for a chance to win a \$100 gift card with one winner per registry.

## Measures

Study participants completed a one-time multi-part question survey to ascertain receipt of pre-operative imaging and patient-reported outcomes of decision quality and regret.

**Pre-operative breast MRI**—Women self-reported receipt of different breast imaging modalities used prior to their first surgical treatment. Women were asked “Which tests did you receive to screen for and diagnose your breast cancer?” Women could mark any imaging that applied. Potential responses included mammogram-digital, mammogram-tomosynthesis, mammogram but don’t know what type, ultrasound, and breast MRI. Women who affirmatively marked receipt of breast MRI were categorized as “yes” to pre-operative breast MRI.

**Patient-reported outcome measures**—Our primary outcomes assessed decision quality and regret. We used the Decision process score derived from the Breast Cancer Surgery Decision Quality Instrument (BCS-DQI) developed by Sepucha et al.<sup>18-20</sup> Seven items assessed the (i) discussion of options of mastectomy and lumpectomy (yes/no), (ii) amount of discussion of pros of each surgery (a lot/some/a little/not at all), (iii) amount of discussion of cons of each surgery (a lot/some/a little/not at all) and (iv) discussion of patients’ goals and treatment preferences (yes/no). Each item with a response of ‘yes’ or ‘a lot/some’ received one point, and all other responses received no points. A total decision process score was calculated by summing the points, dividing by seven, and multiplying by 100, resulting in scores from 0 to 100% with higher scores indicating more shared decision making. Respondents need to have answered >50% of questions to calculate the score.

We assessed the Decision Regret Scale developed by O’Connor et al,<sup>21</sup> as a *measure of distress or remorse after a healthcare decision (i.e., breast cancer surgery for this study)* using 5 multiple choice items. Scores were converted to a 0-100 scale, with higher scores indicating more decisional regret. Overall, a high proportion of women reported no Decision Regret and overall mean was low (mean 9.9/100 in no pre-operative breast MRI group). Hence, Decision Regret is reported as a binary measure of any regret (score>0) versus no regret (score 0).

To explore associations in which pre-operative breast MRI influence women’s perceptions of breast cancer surgery decisions, participants also self-reported as secondary outcomes: a) treatment decisions considerations (i.e., How important was the cost of treatment in deciding what treatment you would receive for your breast cancer? How important was minimizing time missed from work or from other responsibilities in deciding what treatment you would receive for your breast cancer?); b) cancer worry measured by the Lerman Cancer Worry scale;<sup>22</sup> and c) uncertainty with treatment decision measured by Decisional Conflict Scale.<sup>23</sup>

**Breast density prior to breast cancer diagnosis**—We linked study participants to breast density measure captured during routine screening mammography and documented within a BCSC registry before breast cancer diagnosis. Breast density was categorized according to the American College of Radiology's (ACR) Breast Imaging-Reporting and Data System (BI-RADS).<sup>24</sup> Almost entirely fatty and scattered fibroglandular densities were considered “non-dense” breasts, and heterogeneously dense and extremely dense were considered “dense” breasts. Breast density was the only analytic variable ascertained from BCSC data systems.

**Demographics and clinical characteristics**—Participants self-reported demographics (i.e., age, race/ethnicity, living arrangement), education and socioeconomic status (i.e., educational attainment, working status, health insurance), breast cancer characteristics (i.e., mode of primary cancer detection, stage at diagnosis), and treatment (i.e., first surgical treatment, subsequent treatment).

### Statistical Analysis

We calculated descriptive statistics for all variables by calculating frequencies for categorical variables and means with standard deviations for continuous variables. The analytic dataset excluded participants with missing report of pre-operative imaging (n=51) or without a measure of breast density (n=25). For our two primary outcomes, we tested the distribution as continuous outcomes and determined that responses were not normally distributed. Therefore, we used nonparametric Wilcoxon rank-sum test for comparing continuous outcome (BCS-DQI Decision process score) between two groups (yes vs no pre-operative breast MRI). We used Chi-square test for differences between groups for categorical variables and a binary outcome (Decision Regret Scale).

Models were estimated using the SAS PROC GENMOD procedure with linear link to analyze non-normal continuous outcomes and logit link for binary outcomes (SAS version 9.4, Cary, NC). Covariates considered are described in Table 1 and Table 2. Breast density, pre-operative breast MRI, and age at survey were identified *a priori* and included in all multivariable models. To select additional covariates for inclusion in adjusted models, we used the GLMSELECT procedure in SAS with the stepwise variable selection method (entry  $p < 0.1$ , removal  $p > 0.05$ ). The only additional covariate that qualified for inclusion was cancer worry. In addition to age at survey, cancer worry, breast density, and pre-operative breast MRI, final models included a product term between breast density and pre-operative breast MRI. Statistical significance was defined as  $p < 0.05$  based on a 2-sided hypothesis test with no adjustments made for multiple comparisons.

## RESULTS

Overall survey participation rate was 27.9% among eligible respondents (957 eligible participants with complete data/3,430 contacted participants). Majority of surveys were completed online (87%), followed by 13% completed as paper surveys. Less than 1% were completed by phone.

Overall study population was primarily >60 years, White, college educated, and diagnosed with early-stage breast cancer. Among respondents, 45.8% reported pre-operative breast MRI (438/957) (Table 1). Women with dense breasts were more likely to report a pre-operative breast MRI compared to women with non-dense breasts (51% vs. 40%, respectively) (Table 1).

Compared with women who did not receive pre-operative breast MRI, women who received a pre-operative breast MRI were more likely to be <50 years old, commercially insured, and to have self-detected their breast cancer. Women who received pre-operative breast MRI were also more likely to report a mastectomy as their first cancer surgery (Table 1). Patterns remained similar when stratified by breast density for most characteristics, except first cancer surgery. Lower proportion of women with non-dense breasts reported mastectomy (25%) compared with women with dense breasts (36%) in those who received a pre-operative breast MRI.

For most women overall, neither cost nor time missed from work were an important consideration in cancer treatment decisions (Table 2). Self-reported cancer worry was low overall. Overall, measures of cancer worry were clinically similar but statistically significantly different ( $p < 0.002$ ) among women who received (11.6) vs. did not receive (10.8) pre-operative breast MRI in univariate analysis. In stratified analyses by breast density, patterns observed in the overall population remained similar.

In multivariable adjusted models, pre-operative breast MRI use was associated with improved decision quality relative to women who did not receive breast MRI (mean 69.5 vs 64.7, absolute difference 4.8,  $p = 0.004$ ) (Table 3). Study results remained similar when stratified by breast density; however, among women with non-dense breasts, the difference in decision quality widened between women who did and did not receive pre-operative breast MRI (absolute difference 6.0,  $p = 0.016$ ). No statistically significant interaction by breast density group was observed ( $p$ -interaction=0.44).

Univariate associations between pre-operative breast MRI use were associated with greater decision regret (53% for users and 47% among non-users) (Table 4). Although the magnitude of the effect remained similar, there was no difference in decision regret after multivariable adjustment (54.2% vs 48.7%,  $p = 0.11$ ). Further, there were no differences in study results when stratified by breast density and no statistically significant interaction ( $p$ -interaction=0.71).

## DISCUSSION

Our study is among the first to evaluate women's perceptions of decision quality and regret related to breast cancer surgery by pre-operative breast MRI receipt and clinical breast density status. Overall, our results indicate that using pre-operative breast MRI is associated with a small increase in the decision quality measured as a process score relative to women who did not receive pre-operative breast MRI. Further, we found no association between pre-operative breast MRI use and decision regret. Similar patterns of pre-operative breast MRI and decision quality and regret were observed when stratified by breast density,

indicating that breast density does not modify the observed relationship among women in early breast cancer survivorship. Our study results refute prior suggestions that use of breast MRI could be associated with worse patient outcomes.<sup>6</sup>

Higher scores in decision quality indicate improvement in surgical treatment decision making with providers.<sup>18</sup> Decision quality measured in the study population is similar to other breast cancer survivor populations (67.5%<sup>25</sup>), which is indicative of moderate involvement in decision-making. Given that our overall measure aligns with prior reports, it is uncertain whether the absolute difference in scores results in clinically meaningful differences based on receipt of breast MRI. These measure differences equate to answering one additional question affirmatively, on average, in women who received pre-operative breast MRI compared to women who did not receive breast MRI. Our cross-sectional survey was conducted after decisions and cancer surgery were completed. It was not feasible to evaluate whether higher decision quality was influenced by pre-operative breast MRI alone or by other aspects of breast cancer treatment decision making such as the use of decision aids,<sup>26</sup> and/or factors related to the surgeon, which were beyond the focus of our study. A recent trial of breast cancer surgery conversation aids has reported surgeon-specific variation in decision quality.<sup>27</sup> It is plausible that receipt of pre-operative breast MRI could lead to more detailed discussions regarding surgical treatment decisions, given the additional imaging results to evaluate for extent of disease could alter initial surgical plans. Nonetheless, clinicians should provide comprehensive shared-decision making with use of decision aids to all women, regardless of imaging received.

Overall, nearly half of women reported some low-level of decision regret with breast cancer treatment. The proportion reporting some regret did not differ by receipt of breast MRI nor when stratified by breast density. Our study population reported a higher burden of some decision conflict, among women who considered both lumpectomy and mastectomy. Prior studies documented 8-27% women with treated breast cancer experience decision conflict,<sup>28</sup> when women considered bilateral mastectomy with only one affected breast. Contralateral mastectomy is associated with increased cancer distress, poor body image, and decreased self-reported quality of life.<sup>29</sup> As a cross-sectional study, we do not have additional details about the context in which women considered surgical treatment to determine what led to elevated reports of decision regret. Our measure of decision regret could be elevated by categorizing women with any reported regret, even if low level. Further, these perspectives will reflect the experiences of the type of women participating in the survey (i.e., older White women with health insurance) in our survey rather than of the more heterogeneous population of women with treated breast cancer. Since pre-operative breast MRI is associated with increased rates of mastectomy<sup>30</sup> and might have been relevant in contributing to women's perceptions, additional studies are warranted in understanding the impact of breast MRI on decision regret in more diverse populations.

We stratified all analyses by breast density, which could be a driver of additional imaging with breast MRI.<sup>31</sup> Our study results showed that a higher proportion of women with dense breasts received breast MRI than women with non-dense breasts. Use of breast MRI is associated with higher breast biopsy rates without additional cancer detection among women with dense breasts.<sup>32</sup> However, regardless of potentially more intense work-up



among women with dense breasts, we observed no meaningful differences between women with dense breast versus with non-dense breasts in the association between breast MRI on decision quality or regret even when accounting for cancer worry.

Our study has several strengths including a national sample of women, a sufficient sample to measure differences by both pre-operative breast MRI and clinically measured breast density, and validated decision quality and decisional regret measures.<sup>18 19-21</sup> However, there remain some limitations. First, our pre-operative breast MRI definition was defined by asking women to report what tests they received to “screen for and diagnosis their breast cancer”, which may include some screening breast MRI. Breast MRIs received for screening vs. as a preoperative exam are the same procedure, the relevant scan is still within the pre-operative window considered for exposure. Additionally, we are unaware of studies that have reported the accuracy of breast imaging received during the diagnostic work-up vs. self-report. However, prior studies have demonstrated high concordance of women’s self-report of receipt of breast cancer treatment.<sup>33</sup> Misclassification of study exposure is likely low, given these findings. We assessed perceptions about 6-18 months after diagnosis, which might have attenuated women’s responses. Previous reports assessing longitudinal Breast Cancer Surgery-Decision Quality Instrument one year after diagnosis were valid relative to 1 month after diagnosis.<sup>18</sup> Given this, recall bias is likely minimized given the timeframe of outcome ascertainment. Nonetheless, women might have perceived their experiences differently if they had experienced breast cancer recurrence or another breast cancer event, data not collected. By restricting the population of women self-reporting outcomes to within 18 months of the primary breast cancer diagnosis, we minimized the likelihood that a recurrence would have occurred at the time women responded to the survey. Our study participation might not reflect the experiences of all women diagnosed stage 0-III breast, potentially limiting generalizability of study findings. Differences in both study outcomes might differ among more diverse women and warrant further study. Given the scarcity of studies on patient reported outcomes, our results fill a critical gap in understanding women’s perceptions of the downstream consequences for women on the use of pre-operative breast MRI.

Overall, use of pre-operative breast MRI was associated with slightly improved decision quality for breast cancer treatment without impacting decision regret. Breast MRI use in the diagnostic work up of breast cancer was not associated with negative perceptions of cancer treatment decisions early in survivorship. Breast MRI use in the diagnostic work-up of breast cancer does not negatively alter women’s perceptions of surgical treatment decisions in early survivorship. Further studies should evaluate whether these studies findings hold or vary in more diverse women treated for breast cancer.

## THE ROLE OF THE FUNDER

Research reported in this work was funded through a Patient-Centered Outcomes Research Institute (PCORI) award (PCS-1504-30370). Data collection for this research was additionally supported by the Breast Cancer Surveillance Consortium with funding from the National Cancer Institute (P01CA154292, U54CA163303), the Agency for Health Research and Quality (R01 HS018366-01A1), the UC Davis Clinical and Translational Science Center, the UC Davis Comprehensive Cancer Center, and the Placer County Breast Cancer Foundation. The collection of cancer data used in this study was supported in part by several U.S. state public health departments and cancer registries (<https://www.bscs-research.org/about/work-acknowledgement>). All statements in this report, including

its findings and conclusions, are solely those of the authors and do not necessarily represent the views of the Patient-Centered Outcomes Research Institute (PCORI), its Board of Governors or Methodology Committee, nor those of the National Cancer Institute or the National Institutes of Health. We thank the participating women, mammography facilities, and radiologists for the data they have provided for this study. You can learn more about the BCSC at: <http://www.bsc-research.org/>.

## DATA SHARING

The datasets generated during and analyzed during the current study are not publicly available until remaining analyses are complete but may be available on reasonable request from the senior author Dr. Anna Tosteson at [anna.n.a.tosteson@dartmouth.edu](mailto:anna.n.a.tosteson@dartmouth.edu).

## REFERENCES

1. Killelea BK, Long JB, Chagpar AB, et al. Trends and clinical implications of preoperative breast MRI in Medicare beneficiaries with breast cancer. *Breast Cancer Res Treat.* Aug 2013;141(1):155–63. doi:10.1007/s10549-013-2656-1 [PubMed: 23942872]
2. Henderson LM, Weiss J, Hubbard RA, et al. Factors Associated with Preoperative Magnetic Resonance Imaging Use among Medicare Beneficiaries with Nonmetastatic Breast Cancer. *Breast J.* Jan-Feb 2016;22(1):24–34. doi:10.1111/tbj.12522 [PubMed: 26511204]
3. National Comprehensive Cancer Network. National Comprehensive Cancer Network: NCCN Guidelines Version 1.2021 National Comprehensive Cancer Network. Accessed March 1, 2021. <https://jnccn.org/abstract/journals/jnccn/16/3/article-p310.xml>
4. Houssami N, Ciatto S, Macaskill P, et al. Accuracy and surgical impact of magnetic resonance imaging in breast cancer staging: systematic review and meta-analysis in detection of multifocal and multicentric cancer. *Meta-Analysis Review. J Clin Oncol.* Jul 1 2008;26(19):3248–58. doi:10.1200/JCO.2007.15.2108 [PubMed: 18474876]
5. Onega T, Zhu W, Weiss JE, et al. Preoperative breast MRI and mortality in older women with breast cancer. *Breast Cancer Res Treat.* Jul 2018;170(1):149–157. doi:10.1007/s10549-018-4732-z [PubMed: 29516372]
6. Young P, Kim B, Malin JL. Preoperative breast MRI in early-stage breast cancer. *Breast Cancer Res Treat.* Oct 2012;135(3):907–12. doi:10.1007/s10549-012-2207-1 [PubMed: 22923237]
7. Liberman L. Breast MR imaging in assessing extent of disease. *Magn Reson Imaging Clin N Am.* Aug 2006;14(3):339–49, vi. doi:10.1016/j.mric.2006.07.007 [PubMed: 17098175]
8. Morrow M, Freedman G. A clinical oncology perspective on the use of breast MR. *Magn Reson Imaging Clin N Am.* Aug 2006;14(3):363–78, vi. doi:10.1016/j.mric.2006.07.006 [PubMed: 17098177]
9. Smith RA. The evolving role of MRI in the detection and evaluation of breast cancer. *N Engl J Med.* Mar 29 2007;356(13):1362–4. doi:10.1056/NEJMe078006 [PubMed: 17392307]
10. Montgomery M, McCrone SH. Psychological distress associated with the diagnostic phase for suspected breast cancer: systematic review. *J Adv Nurs.* Nov 2010;66(11):2372–90. doi:10.1111/j.1365-2648.2010.05439.x [PubMed: 21039773]
11. Bond M, Pavey T, Welch K, et al. Systematic review of the psychological consequences of false-positive screening mammograms. *Health Technol Assess.* Mar 2013;17(13):1–170, v-vi. doi:10.3310/hta17130
12. Onega T, Tosteson AN, Weiss J, et al. Costs of diagnostic and preoperative workup with and without breast MRI in older women with a breast cancer diagnosis. *BMC Health Serv Res.* Feb 27 2016;16:76. doi:10.1186/s12913-016-1317-6 [PubMed: 26920552]
13. Holland K, van Gils CH, Mann RM, Karssemeijer N. Quantification of masking risk in screening mammography with volumetric breast density maps. *Breast Cancer Res Treat.* Apr 2017;162(3):541–548. doi:10.1007/s10549-017-4137-4 [PubMed: 28161786]
14. Raghavendra A, Sinha AK, Le-Petross HT, et al. Mammographic breast density is associated with the development of contralateral breast cancer. *Cancer.* Jun 1 2017;123(11):1935–1940. doi:10.1002/cncr.30573 [PubMed: 28135395]

15. Breast Cancer Surveillance Consortium. Breast Cancer Surveillance Consortium Homepage. Accessed August 20, 2019. <http://www.bscs-research.org/>
16. Ballard-Barbash R, Taplin SH, Yankaskas BC, et al. Breast Cancer Surveillance Consortium: a national mammography screening and outcomes database. *AJR Am J Roentgenol.* Oct 1997;169(4):1001–8. doi:10.2214/ajr.169.4.9308451 [PubMed: 9308451]
17. Griffin JM, Simon AB, Hulbert E, et al. A comparison of small monetary incentives to convert survey non-respondents: a randomized control trial. *BMC Med Res Methodol.* May 26 2011;11:81. doi:10.1186/1471-2288-11-81 [PubMed: 21615955]
18. Sepucha KR, Langford AT, Belkora JK, et al. Impact of Timing on Measurement of Decision Quality and Shared Decision Making: Longitudinal Cohort Study of Breast Cancer Patients. *Medical decision making : an international journal of the Society for Medical Decision Making.* Aug 2019;39(6):642–650. doi:10.1177/0272989x19862545 [PubMed: 31354095]
19. Lee CN, Chang Y, Adimorah N, et al. Decision making about surgery for early-stage breast cancer. *J Am Coll Surg.* Jan 2012;214(1):1–10. doi:10.1016/j.jamcollsurg.2011.09.017 [PubMed: 22056355]
20. Sepucha KR, Belkora JK, Chang Y, et al. Measuring decision quality: psychometric evaluation of a new instrument for breast cancer surgery. *BMC Med Inform Decis Mak.* Jun 8 2012;12:51. doi:10.1186/1472-6947-12-51 [PubMed: 22681763]
21. O'Connor A. User Manual-Decision Regret Scale. Document on the Internet. Ottawa: Ottawa Hospital Research Institute. Updated 2003. Accessed March 1, 2021. [http://decisionaid.ohri.ca/docs/develop/User\\_Manuals/UM\\_Regret\\_Scale.pdf](http://decisionaid.ohri.ca/docs/develop/User_Manuals/UM_Regret_Scale.pdf)
22. Lerman C, Trock B, Rimer BK, Jepson C, Brody D, Boyce A. Psychological side effects of breast cancer screening. *Health psychology : official journal of the Division of Health Psychology, American Psychological Association.* 1991;10(4):259–267. doi:10.1037//0278-6133.10.4.259 [PubMed: 1915212]
23. O'Connor AM. Validation of a decisional conflict scale. *Medical decision making : an international journal of the Society for Medical Decision Making.* Jan-Mar 1995;15(1):25–30. doi:10.1177/0272989X9501500105 [PubMed: 7898294]
24. D'Orsi C, Sickles E, Mendelson E, Morris E, al. E. ACR BI-RADS Atlas, Breast Imaging Reporting and Data System. Fifth ed. American College of Radiology; 2013.
25. Sepucha K, Feibelman S, Chang Y, Hewitt S, Ziogas A. Measuring the quality of surgical decisions for Latina breast cancer patients. *Health Expect.* Dec 2015;18(6):2389–400. doi:10.1111/hex.12207 [PubMed: 24813584]
26. Waljee JF, Rogers MA, Alderman AK. Decision aids and breast cancer: do they influence choice for surgery and knowledge of treatment options? *J Clin Oncol.* Mar 20 2007;25(9):1067–73. doi:10.1200/JCO.2006.08.5472 [PubMed: 17369570]
27. Durand MA, Yen RW, O'Malley AJ, et al. What matters most: Randomized controlled trial of breast cancer surgery conversation aids across socioeconomic strata. *Cancer.* Feb 1 2021;127(3):422–436. doi:10.1002/cncr.33248 [PubMed: 33170506]
28. Manne S, Smith B, Mitarotondo A, Frederick S, Toppmeyer D, Kirstein L. Decisional conflict among breast cancer patients considering contralateral prophylactic mastectomy. *Patient Educ Couns.* May 2019;102(5):902–908. doi:10.1016/j.pec.2018.12.008 [PubMed: 30553577]
29. Parker PA, Peterson SK, Shen Y, et al. Prospective Study of Psychosocial Outcomes of Having Contralateral Prophylactic Mastectomy Among Women With Nonhereditary Breast Cancer. *J Clin Oncol.* Sep 1 2018;36(25):2630–2638. doi:10.1200/jco.2018.78.6442 [PubMed: 30044695]
30. Bleicher RJ, Ciocca RM, Egleston BL, et al. Association of routine pretreatment magnetic resonance imaging with time to surgery, mastectomy rate, and margin status. *J Am Coll Surg.* Aug 2009;209(2):180–7; quiz 294-5. doi:10.1016/j.jamcollsurg.2009.04.010 [PubMed: 19632594]
31. Hill DA, Haas JS, Wellman R, et al. Utilization of breast cancer screening with magnetic resonance imaging in community practice. *J Gen Intern Med.* Mar 2018;33(3):275–283. doi:10.1007/s11606-017-4224-6 [PubMed: 29214373]
32. Onega T, Zhu W, Kerlikowske K, et al. Preoperative MRI in breast cancer: effect of breast density on biopsy rate and yield. *Breast Cancer Res Treat.* Oct 22 2021;doi:10.1007/s10549-021-06418-x

33. Gast KC, Cathcart-Rake EJ, Norman A, et al. Accuracy of self-reported cancer treatment data in young breast cancer survivors. *J Patient Rep Outcomes*. May 1 2019;3(1):24. doi:10.1186/s41687-019-0114-5 [PubMed: 31041547]

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

**TABLE 1.** Self-reported characteristics of study population by receipt of pre-operative breast MRI, overall and stratified by breast density.

Characteristic	Overall		Non-dense breasts*		Dense breasts*	
	Pre-operative breast MRI		Pre-operative breast MRI		Pre-operative breast MRI	
	Yes N (%)	No N (%)	Yes N (%)	No N (%)	Yes N (%)	No N (%)
<b>Total</b>	438	519	167	254	271	265
<b>Demographics</b>						
<b>Age, years</b>						
< 50	69 (16%)	50 (10%)	11 (7%)	12 (5%)	58 (21%)	38 (14%)
50-59	113 (26%)	112 (22%)	27 (16%)	50 (20%)	86 (32%)	62 (23%)
60-69	167 (38%)	184 (35%)	78 (47%)	98 (39%)	89 (33%)	86 (32%)
70+	87 (20%)	168 (32%)	49 (29%)	90 (35%)	38 (14%)	78 (29%)
<b>Race and ethnicity</b>						
White, non-Hispanic	376 (86%)	453 (87%)	145 (87%)	222 (87%)	231 (85%)	231 (87%)
Black, non-Hispanic	25 (6%)	19 (4%)	10 (6%)	9 (4%)	15 (6%)	10 (4%)
Asian/Native Hawaiian or Other Pacific Islander	17 (4%)	16 (3%)	5 (3%)	5 (2%)	12 (4%)	11 (4%)
Hispanic	14 (3%)	22 (4%)	4 (2%)	13 (5%)	10 (4%)	9 (3%)
Native American/Mixed/Other	4 (1%)	5 (1%)	1 (1%)	4 (2%)	3 (1%)	1 (0%)
<b>Education</b>						
High school or less	45 (10%)	65 (13%)	21 (13%)	43 (17%)	24 (9%)	22 (8%)
Some college	125 (29%)	164 (32%)	58 (35%)	94 (37%)	67 (25%)	70 (27%)
College graduate	100 (23%)	104 (20%)	33 (20%)	37 (15%)	67 (25%)	67 (26%)
Graduate school	166 (38%)	181 (35%)	53 (32%)	78 (31%)	113 (42%)	103 (39%)
<b>Rural/urban residence</b>						
Rural	43 (10%)	53 (10%)	19 (11%)	30 (12%)	24 (9%)	23 (9%)
Urban	395 (90%)	466 (90%)	148 (89%)	224 (88%)	247 (91%)	242 (91%)
<b>Work status</b>						
Working	235 (54%)	242 (47%)	66 (40%)	105 (42%)	169 (62%)	137 (52%)

	Overall				Non-dense breasts*				Dense breasts*			
	Pre-operative breast MRI		breast MRI		Pre-operative breast MRI		breast MRI		Pre-operative breast MRI		breast MRI	
	Yes	No	Yes	No	Yes	No	Yes	No	Yes	No	Yes	No
	N (%)	N (%)	N (%)	N (%)	N (%)	N (%)	N (%)	N (%)	N (%)	N (%)	N (%)	N (%)
<b>Characteristic</b>												
Retired	183 (42%)	252 (49%)	92 (55%)	135 (53%)	91 (34%)	117 (44%)						
Unemployed/Disabled	15 (3%)	18 (3%)	7 (4%)	10 (4%)	8 (3%)	8 (3%)						
<b>Insurance status</b>												
Commercial	266 (61%)	251 (48%)	75 (45%)	103 (41%)	191 (70%)	148 (56%)						
Medicare	164 (37%)	258 (50%)	88 (53%)	145 (57%)	76 (28%)	113 (43%)						
Medicaid	6 (1%)	8 (2%)	3 (2%)	4 (2%)	3 (1%)	4 (2%)						
<b>First degree family history of breast cancer</b>												
Yes	136 (31%)	144 (28%)	47 (28%)	60 (24%)	89 (33%)	84 (32%)						
No	297 (68%)	364 (70%)	117 (70%)	187 (74%)	180 (66%)	177 (67%)						
I don't know	5 (1%)	10 (2%)	3 (2%)	6 (2%)	2 (1%)	4 (2%)						
<b>Breast cancer diagnosis</b>												
<b>Mode of detection</b>												
Self-detected	127 (29%)	107 (21%)	37 (22%)	46 (18%)	90 (33%)	61 (23%)						
Screening mammogram	269 (61%)	379 (73%)	123 (74%)	190 (75%)	146 (54%)	189 (71%)						
Clinical detection	41 (9%)	31 (6%)	7 (4%)	16 (6%)	34 (13%)	15 (6%)						
<b>Stage at diagnosis</b>												
DCIS	81 (18%)	105 (20%)	39 (23%)	57 (22%)	55 (20%)	69 (26%)						
I	234 (53%)	268 (52%)	75 (45%)	129 (51%)	128 (47%)	107 (40%)						
II	86 (20%)	99 (19%)	39 (23%)	47 (19%)	60 (22%)	62 (23%)						
III	24 (5%)	28 (5%)	7 (4%)	11 (4%)	21 (8%)	16 (6%)						
Not certain	13 (3%)	19 (4%)	7 (4%)	10 (4%)	7 (3%)	11 (4%)						
Time from diagnosis to first cancer surgery, months												
<1	81 (18%)	144 (28%)	26 (16%)	78 (31%)	55 (20%)	66 (25%)						
1-2	200 (46%)	238 (46%)	80 (48%)	115 (45%)	120 (44%)	123 (46%)						
2-3	84 (19%)	66 (13%)	39 (23%)	29 (11%)	45 (17%)	37 (14%)						

	Overall				Non-dense breasts*				Dense breasts*			
	Pre-operative breast MRI		breast MRI		Pre-operative breast MRI		breast MRI		Pre-operative breast MRI		breast MRI	
	Yes	No	Yes	No	Yes	No	Yes	No	Yes	No	Yes	No
Characteristic	N (%)	N (%)	N (%)	N (%)	N (%)	N (%)	N (%)	N (%)	N (%)	N (%)	N (%)	N (%)
>3	67 (15%)	57 (11%)	19 (11%)	25 (10%)	48 (18%)	32 (12%)						
<b>First cancer surgery</b>												
Lumpectomy	294 (67%)	397 (77%)	122 (73%)	208 (83%)	172 (63%)	189 (71%)						
Mastectomy	140 (32%)	108 (21%)	42 (25%)	39 (15%)	98 (36%)	69 (26%)						
No surgical treatment	4 (1%)	12 (2%)	3 (2%)	5 (2%)	1 (0%)	7 (3%)						
<b>Additional treatment received after first cancer surgery</b>												
Mastectomy	29 (7%)	32 (6%)	9 (6%)	17 (7%)	20 (7%)	15 (6%)						
Breast reconstruction surgery	89 (21%)	46 (9%)	29 (18%)	12 (5%)	60 (22%)	34 (13%)						
Radiation therapy	264 (61%)	338 (67%)	103 (63%)	167 (68%)	161 (60%)	171 (66%)						
Hormone therapy	212 (49%)	241 (48%)	74 (45%)	113 (46%)	138 (51%)	128 (50%)						
Chemotherapy	114 (26%)	107 (21%)	40 (25%)	51 (21%)	74 (27%)	56 (22%)						
No additional treatment	41 (9%)	56 (11%)	22 (13%)	26 (11%)	19 (7%)	30 (12%)						

\* Breast density was collected from the clinical interpretation based on most recent mammogram before cancer diagnosis documented in BCSC.

Self-report of breast cancer treatment decision, cancer worry and conflict associated with pre-op breast MRI, overall and by breast density

TABLE 2:

	Overall				Non-dense breasts				Dense breasts				
	Pre-operative breast MRI		p-value*	No N (%)	Pre-operative breast MRI		p-value*	No N (%)	Pre-operative breast MRI		p-value*	No N (%)	
	Yes N (%)	No N (%)			Yes N (%)	No N (%)			Yes N (%)	No N (%)			
<b>Characteristic</b>													
<b>Treatment decision</b>													
How important was the <b>cost</b> of treatment in deciding what treatment you would receive for your breast cancer?			0.15							0.044			0.98
Not at all	297 (68%)	370 (71%)		109 (65%)	183 (72%)		188 (69%)	187 (71%)					
Slightly	64 (15%)	55 (11%)		28 (17%)	26 (10%)		36 (13%)	29 (11%)					
Moderately	32 (7%)	32 (6%)		13 (8%)	12 (5%)		19 (7%)	20 (8%)					
Very	12 (3%)	20 (4%)		5 (3%)	13 (5%)		7 (3%)	7 (3%)					
Extremely	22 (5%)	20 (4%)		8 (5%)	6 (2%)		14 (5%)	14 (5%)					
I prefer not to answer	9 (2%)	20 (4%)		3 (2%)	13 (5%)		6 (2%)	7 (3%)					
How important was <b>minimizing time missed from work</b> or from other responsibilities in deciding what treatment you would receive for your breast cancer?			0.44							0.67			0.79
Not at all	250 (57%)	326 (63%)		107 (64%)	170 (67%)		143 (53%)	156 (59%)					
Slightly	83 (19%)	79 (15%)		23 (14%)	31 (12%)		60 (22%)	48 (18%)					
Moderately	42 (10%)	52 (10%)		12 (7%)	25 (10%)		30 (11%)	27 (10%)					
Very	33 (8%)	30 (6%)		13 (8%)	13 (5%)		20 (7%)	17 (6%)					
Extremely	25 (6%)	25 (5%)		10 (6%)	11 (4%)		15 (6%)	14 (5%)					
I prefer not to answer	4 (1%)	5 (1%)		1 (1%)	3 (1%)		3 (1%)	2 (1%)					
<b>Cancer worry scale<sup>‡</sup></b>													
Mean (SD)	11.6 (3.7)	10.8 (3.5)		11.2 (3.6)	10.9 (3.5)		11.8 (3.7)	10.7 (3.6)					
Median	11	10	0.002	11	10		11	10		0.38	11	10	<0.001
Min, Max	4, 24	2, 24		4, 22	2, 21		6, 24	3, 24					



Characteristic	Overall				Non-dense breasts				Dense breasts			
	Pre-operative breast MRI		p-value*	Pre-operative breast MRI		p-value*	Pre-operative breast MRI		p-value*	Pre-operative breast MRI		* p-value
	Yes	No		Yes	No		Yes	No		Yes	No	
Q1, Q3	9, 14	8, 13		8, 13	8, 13		9, 14	8, 13		9, 14	8, 13	
<b>Decisional conflict scale<sup>§</sup></b>												
Mean (SD)	6.0 (14.3)	6.2 (14.4)		5.7 (14.6)	6.1 (13)		6.2 (14.1)	6.3 (15.7)		6.2 (14.1)	6.3 (15.7)	
Median	0	0	0.23	0	0	0.084	0	0		0	0	0.96
Min, Max	0, 80	0, 95		0, 75	0, 85		0, 80	0, 95		0, 80	0, 95	
Q1, Q3	0, 0	0, 5		0, 0	0, 10		0, 5	0, 5		0, 5	0, 5	

\* p-values were based on Chi-square test for categorical variables and two-sample nonparametric Wilcoxon rank-sum test for continuous variables.

<sup>†</sup>The Lerman cancer worry scale ranges from 6 to 24 with higher scores indicating more frequent worries about cancer.

<sup>§</sup>Decisional Conflict Scale scores range from 0 to 100, with 0 indicating extremely certain about best choice and 100 indicating extremely uncertain about best choice.

**TABLE 3.**

The association of pre-operative breast MRI on unadjusted and adjusted outcomes on the Breast Cancer Surgery Decision Quality Instrument\*, overall and by breast density.

	Overall			Non-dense breasts			Dense breasts		
	Pre-operative breast MRI		p-value	Pre-operative breast MRI		p-value	Pre-operative breast MRI		p-value
	Yes	No		Yes	No		Yes	No	
<b>Unadjusted</b>			<0.001			0.007			0.041
Mean (SD)	69.4 (24.5)	63.7 (25.8)		69.0 (24.8)	62.6 (24.9)		69.7 (24.4)	64.8 (26.6)	
Median	71	71		71	57		71	71	
Q1, Q3	57, 86	43, 86		57, 86	43, 86		57, 86	43, 86	
<b>Adjusted<sup>‡</sup></b>									
Mean (SE)	69.5 (1.28)	64.7 (1.18)	0.004	70.1 (2.03)	64.1 (1.67)	0.016	68.9 (1.54)	65.4 (1.57)	0.11

Abbreviations: SD, standard deviation; SE, standard error

\* The Decision Quality Instrument - decision process score ranges from 0-100%, with higher scores indicating more shared decision making.

<sup>‡</sup>Primary model adjusted for: age at survey, cancer worry, and breast density. Stratified model was adjusted for age at survey, cancer worry, breast density, pre-operative breast MRI, and interaction between density and pre-operative breast MRI.

The association of pre-operative breast MRI on unadjusted and adjusted outcomes on the Decision Regret Scale<sup>\*</sup>, overall and by breast density.

**TABLE 4.**

	Overall				Non-dense breasts				Dense breasts			
	Pre-operative breast MRI		p-value	Pre-operative breast MRI		p-value	Pre-operative breast MRI		p-value	Pre-operative breast MRI		p-value
	Yes	No		Yes	No		Yes	No		Yes	No	
<b>Unadjusted</b>			<b>0.049</b>								<b>0.037</b>	
None	204 (47%)	276 (53%)		76 (46%)	126 (50%)		128 (47%)	150 (57%)				
Any	234 (53%)	243 (47%)		91 (54%)	128 (50%)		143 (53%)	115 (43%)				
<b>Adjusted<sup>‡</sup></b>			0.11								0.13	
None	45.8%	51.3%		43.4%	47.6%		48.8%	55.0%				
Any	54.2%	48.7%		56.6%	52.4%		51.2%	45.0%				

<sup>\*</sup> Decision regret scale is dichotomized as any (Score >0) versus none (0).

<sup>‡</sup> Primary model adjusted for: age at survey, cancer worry, and breast density. Stratified model was adjusted for age at survey, cancer worry, breast density, pre-operative breast MRI, and interaction between density and pre-operative breast MRI.